研究業績：臨床試験部｜千葉大学病院未来開拓センター

臨床試験部

Yamaguchi N, Misawa S, Sato Y, Nagashima K, Katayama K, Sekiguchi Y, Iwai Y, Amino H, Suichi T, Yokota T, Nishida Y, Kohara N, Hirata K, Nishiyama K, Yabe I, Kaida KI, Suzuki N, Nodera H, Tsuji S, Koike H, Kira JI, Hanaoka H, Kusunoki S, Kuwabara S; JET-GBS Group. A Prospective, Multicenter, Randomized Phase II Study to Evaluate the Efficacy and Safety of Eculizumab in Patients with Guillain-Barré Syndrome (GBS): Protocol of Japanese Eculizumab Trial for GBS (JET-GBS). JMIR Res Protoc. 2016;5(4):e210.
Misawa S, Sato Y, Katayama K, Nagashima K, Aoyagi R, Sekiguchi Y, Sobue G, Koike H, Yabe I, Sasaki H, Watanabe O, Takashima H, Nishizawa M, Kawachi I, Kusunoki S, Mitsui Y, Kikuchi S, Nakashima I, Ikeda S, Kohara N, Kanda T, Kira J, Hanaoka H, Kuwabara S; Japanese POEMS Syndrome for Thalidomide (J-POST) Trial Study Group. Safety and efficacy of thalidomide in patients with POEMS syndrome: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15(11):1129-1137.
Tanemura N, Uyama Y, Nagashima K, Suzuki T, Asahina Y, Kobayashi Y, Iyo M, Yokote Y, Hanaoka H. Comparison of Drug Use Between Clinical Practice and Regulatory Approval: Results in Older Japanese Patients With Rheumatoid Arthritis, Diabetes, High Blood Pressure, or Depression. Ther Innov Regul Sci. 2016;50(6):743-750.
Mitsuhashi A, Sato Y, Kiyokawa T, Koshizaka M, Hanaoka H, Shozu M. Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. Ann Oncol. 2016;27(2):262-266.
Yoshinaga N, Matsuki S, Niitsu T, Sato Y, Tanaka M, Ibuki H, Takanashi R, Ohshiro K, Ohshima F, Asano K, Kobori O, Yoshimura K, Hirano Y, Sawaguchi K, Koshizaka M, Hanaoka H, Nakagawa A, Nakazato M, Iyo M, Shimizu E. Cognitive Behavioral Therapy for Patients with Social Anxiety Disorder Who Remain Symptomatic following Antidepressant Treatment: A Randomized, Assessor-Blinded, Controlled Trial. Psychother Psychosom. 2016;85(4):208-217.
Aoyagi R, Hamada H, Sato Y, Suzuki H, Onouchi Y, Ebata R, Nagashima K, Terauchi M, Terai M, Hanaoka H, Hata A; KAICA Trial Investigators. KAICA Trial investigators. Study protocol for a phase III multicentre, randomised, open-label, blinded-end point trial to evaluate the efficacy and safety of immunoglobulin plus cyclosporin A in patients with severe Kawasaki disease (KAICA Trial). BMJ Open. 2015;5(12):e009562.
Katayama K, Misawa S, Sato Y, Sobue G, Yabe I, Watanabe O, Nishizawa M, Kusunoki A, Kikuchi S, Nakashima I, Ikeda S, Kohara N, Kanda T, Kira J, Hanaoka H, Kuwabara S.Japanese POEMS syndrome with Thalidomide(J-POST) Trial: study protocol for a phase Ⅱ/Ⅲ multicentre, randomised, double-blind, placebo-controlled trial. BMJ Open. 2015;5(1):e007330.
Misawa S, Sato Y, Katayama K, Hanaoka H, Sawai S, Beppu M, Nomura F, Shibuya K, Sekiguchi Y, Iwai Y, Watanabe K, Amino H, Ohwada C, Takeuchi M, Sakaida E, Nakaseko C, Kuwabara S. Vascular endothelial growth factor as a predictive marker for POEMS syndrome treatment response: retrospective cohort study. BMJ Open.2015;5(11):e009157.
Yokoh H, Kobayashi K, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with lpha-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on metformin or pioglitazone alone (Study for an Ultimate Combination Therapy to Control Diabetes with Sitagliptin-1): A multicenter, randomized, open-label, non-inferiority trial. J Diabetes Investig. 2015;6(2):182-191.
Kobayashi K, Yokoh H, Sato Y, Takemoto M, Uchida D, Kanatsuka A, Kuribayashi N, Terano T, Hashimoto N, Sakurai K, Hanaoka H, Ishikawa K, Onishi S, Yokote K. SUCCESS Study Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin compared with α-glucosidase inhibitor in Japanese patients with type 2 diabetes inadequately controlled on sulfonylurea alone (SUCCESS-2): a multicenter, randomized, open-label, non-inferiority trial. Diabetes Obes Metab. 2014;16(8):761-765.
Yoshinaga N, Niitsu T, Hanaoka H, Sato Y, Ohshima F, Matsuki S, Kobori O, Nakazato M, Nakagawa A, Iyo M, Shimizu E. Strategy for treating selective serotonin reuptake inhibitor-resistant social anxiety disorder in the clinical setting: a randomised controlled trial protocol of cognitive behavioural therapy in combination with conventional treatment. BMJ Open. 2013;3(2):e002242.
Kotooka N, Asaka M, Sato Y, Kinugasa Y, Nochioka K, Mizuno A, Nagatomo D, Mine D, Yamada Y, Eguchi K, Hanaoka H, Inomata T, Fukumoto Y, Yamamoto K, Tsutsui H, Masuyama T, Kitakaze M, Inoue T, Shimokawa H, Momomura S, Seino Y, Node K; HOMES-HF study investigators. Home telemonitoring study for Japanese patients with heart failure (HOMES-HF): protocol for a multicentre randomised controlled trial. BMJ Open. 2013;3(6):e002972.
Sakuma T, Yamazaki M, Okawa A, Takahashi H, Kato K, Hashimoto M, Hayashi K, Furuya T, Fujiyoshi T, Kawabe J, Mannoji C, Miyashita T, Kadota R, Someya Y, Ikeda O, Yamauchi T, Hashimoto M, Aizawa T, Ono A, Imagama S, Kanemura T, Hanaoka H, Takahashi K, Koda M. Neuroprotective therapy using granulocyte colony-stimulating factor for patients with worsening symptoms of thoracic myelopathy: a multicenter prospective controlled trial. Spine. 2012;37(17):1475-1478.
Hanaoka H, Oishi Y, Sakamoto A. Selective Reduction and Recovery of Invariant Vα24JαQ TCR T Cells in Correlation with Disease Activity in Patients with Chronic Graft-versus-Diseases. Chiba Medical Journal. 2009;85(3):113-124.